Eloubeidi et al developed a revised TNM classification for esophageal carcinoma. This incorporates tumor length, number of positive lymph nodes and other pathologic findings to stage the tumor. The authors are from the University of Alabama and the Medical University of South Carolina.
Group |
Findings |
Code |
T |
tumor cannot be assessed |
Tx |
|
no evidence of primary tumor |
T0 |
|
carcinoma in situ |
Tis |
|
tumor invades lamina propria or submucosa |
T1 |
|
tumor invades muscularis propria |
T2 |
|
tumor invades adventitia |
T3 |
|
tumor invades adjacent structures |
T4 |
T subcode |
length <= 3 cm |
a |
|
length > 3 cm |
b |
N |
regional lymph nodes cannot be assessed |
Nx |
|
no regional lymph node metastasis |
N0 |
|
regional lymph node metastases, 1 – 5 |
N1a |
|
regional lymph node metastases, > 5 |
N1b |
M |
distant metastasis cannot be assessed |
Mx |
|
no distant metastasis |
M0 |
|
distant metastasis |
M1 |
from Table 7, page 1442
Segment of Esophagus |
Distant Metastasis |
Designation |
upper thoracic |
to cervical lymph nodes |
M1a |
|
to other distant sites |
M1b |
midthoracic |
NA |
M1a |
|
nonregional lymph nodes and/or other distant sites |
M1b |
lower thoracic |
to celiac lymph nodes |
M1a |
|
to other distant sites |
M1b |
mortality risk based on tumor size in cm =
= 1 – (0.942 * EXP(Y))
where:
Y =
= (0.021 * ((diameter in cm)^2)) – (0.3285 * (diameter in cm))
Specialty: Hematology Oncology, Surgery, general, Gastroenterology
ICD-10: ,